miR-370-3p as a Novel Biomarker Promotes Breast Cancer Progression by Targeting FBLN5

Table 1

Correlation between FBLN5 in breast cancer tissues and clinicopathological parameters.

Clinicopathological information	n	Relative expression of FBLN5	P
Tumor diameter
<=2cm	14	0.481(0.284, 0.915)	0.015
>2cm	6	0.029(0.020, 0.366)
Age
<=50	8	0.630(0.273, 1.049)	0.0836
>50	12	0.312(0.029, 0.452)
Pathological type
Ductal carcinoma in situ	3	0.338(0.028, 2.489)	0.4472
Invasive ductal carcinoma	14	0.316(0.029, 0.588)
Others	3	0.624(0.426, 0.636)
Lymph node metastasis
0	16	0.439(0.222, 0.627)	0.3694
>=1	4	0.187(0.021, 0.542)
TNM staging
I	11	0.503(0.286, 0.844)	0.0227
II	9	0.029(0.028, 0.372)
ER
No data	3	0.503(0.053, 1.663)
-	5	0.028(0.020, 0.643)	0.0651
+	12	0.439 (0.325, 0.627)
PR
No data	3	0.503(0.053, 1.663)
-	5	0.028 (0.020, 0.960)	0.2684
+	12	0.386 (0.284, 0.627)
HER-2
No data	4	0.278 (0.047, 0.793)
+	2	0.435 (0.020, 0.633)	0.6791
++	11	0.451 (0.279, 0.636)
+++	3	0.338 (0.001, 0.426)